









Markets
/
Stocks
/
nasdaq-inab
/

IN8BIO, Inc.

INAB

2.000USD

-0.060-2.91%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

8.16MMarket Cap

LossP/E TTM



IN8BIO, Inc.

2.000

-0.060-2.91%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

260 / 506

Overall Ranking

422 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

63.250

Target Price

+2970.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Overvalued

The company’s latest PE is -0.22, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 913.62K shares, decreasing 13.94% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 60.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.23, which is 8.75% below the recent high of -0.25 and -63.04% above the recent low of -0.37.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 260/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for IN8BIO, Inc. is 35.00, with a high of 180.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

63.250

Target Price

+3062.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

IN8bio Inc

INAB

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.66, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.30 and the support level at 1.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

-0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

41.860

Neutral

STOCH(KDJ)(9,3,3)

36.733

Neutral

ATR(14)

0.114

High Vlolatility

CCI(14)

-49.674

Neutral

Williams %R

74.483

Sell

TRIX(12,20)

-0.454

Sell

StochRSI(14)

29.743

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.016

Sell

MA10

2.035

Sell

MA20

2.128

Sell

MA50

2.205

Sell

MA100

1.722

Buy

MA200

0.986

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 26.39%, representing a quarter-over-quarter decrease of 27.97%. The largest institutional shareholder is The Vanguard, holding a total of 60.10K shares, representing 1.32% of shares outstanding, with 32.61% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bios Equity Partners, LP.

286.67K

Franklin Advisers, Inc.

189.87K

AIGH Capital Management, LLC.

37.43K

-75.81%

Ho (William Tai Wei)

93.45K

Alyeska Investment Group, L.P.

69.32K

-58.93%

The Vanguard Group, Inc.

Star Investors

60.10K

+26.62%

Worth Venture Partners, LLC

10.90K

-78.89%

Brandt (Peter C)

26.23K

+26.32%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.06, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.